Change - Announcement of Appointment::Appointment of Independent Non-Executive Director

Issuer & Securities

Issuer/ Manager
SINGAPORE PAINCARE HOLDINGS LIMITED
Securities
SINGAPORE PAINCARE HOLDINGS LIMITED - SGXE51400773 - FRQ
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
05-Mar-2021 17:30:21
Status
New
Announcement Sub Title
Appointment of Independent Non-Executive Director
Announcement Reference
SG210305OTHRXGTC
Submitted By (Co./ Ind. Name)
Dr. Lee Mun Kam Bernard
Designation
Executive Director and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Appointment of Independent Non-Executive Director.

Singapore Paincare Holdings Limited (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 30 July 2020. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the "Sponsor").

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.

Additional Details

Date Of Appointment
05/03/2021
Name Of Person
Lim Kah Meng
Age
48
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Board of Directors (the "Board"), having considered the recommendation of the Nominating Committee and reviewed the qualification and experience of Dr. Lim Kah Meng ("Dr. Lim"), is of the view that Dr. Lim has the requisite experience and capabilities to assume the duties and responsibilities as the Independent Non-Executive Director of the Company.
Whether appointment is executive, and if so, the area of responsibility
Non-Executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Independent Non-Executive Director
Professional qualifications
Doctor of Philosophy, National University of Singapore

BSc (Hons) in Microbiology, National University of Singapore
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
September 2001 to Current - Gene Oasis Pte. Ltd., Chief Executive Officer
September 2017 to Current - NGF BioEnterprise Pte. Ltd., Managing Director
September 2017 to Current - FEGO Biotech Pte. Ltd., Managing Director
July 2015 to Current - GeneOasis Bioscientific Pte. Ltd., Managing Director
January 2018 to Current - Alphacel Singapore Pte Ltd, Chief Science Advisor
June 2012 to Current - Extend International, Chief Science Officer
January 2014 to December 2016 - Institute of Advanced Technologies (Wuqing) of Tianjin University, Adjunct Associate Professor, Division of Biological Engineering
March 2012 to March 2013 - Nanyang Technological University, Adjunct Assistant Professor, School of Chemical and Biomedical Engineering
July 2012 to January 2014 (Dormant) - South East Asia Bird's Nest Chamber of Commerce, President
January 2010 to January 2012 - Riway (Singapore) Pte. Ltd., Chief Science Officer
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Link Trust Laboratories Pte. Ltd.
Singapore Bio Beauty Group Pte. Ltd.
Well Oasis Pte. Ltd.
GO Bioscience Ventures Pte. Ltd.
Nutra-X Biotech Pte. Ltd.
3 Elemenz Holdings Pte. Ltd.
Cixgen Capital Pte. Ltd.
Golden Yan Ventures Pte. Ltd.
Present
Gene Oasis Bioenterprise Pte. Ltd.
Gene Oasis Pte. Ltd.
GO Biosciences Group Pte. Ltd.
GO Bioenterprise Pte. Ltd.
GeneOasis Bioscientific Pte. Ltd.
Tyrosine Research Laboratories Pte. Ltd.
GO Stem Cell Holdings Pte. Ltd.
FEGO Biotech Pte. Ltd.
NGF Bioenterprise Pte. Ltd.
GO Stem Cell Biomedicals Pte. Ltd.
Green Oasis Therapeutics Pte. Ltd.
Zenzic Labs Pte. Ltd.
Bio Oasis Investments Pte. Ltd.
GO Biomedical Pte. Ltd.
Panthera Labs Pte. Ltd.
Compass Venture Inc. (Canadian Public Listed Company)
Fego Founders Pte. Ltd.
FEGO Oasis Pte. Ltd.
Stemigen Therapeutics Pte. Ltd.
Betalife Pte. Ltd.
Gene Oasis (Malaysia) Sdn Bhd
Gene Oasis EBN Sdn Bhd
Fego Holdings Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Yes, Dr. Lim will be attending the training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange to meet the mandatory training requirements under Rule 406(3)(a) of the SGX-ST Listing Manual Section B: Rules of Catalist.